Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amit M Oza

Showing results (1-10 of 250) with videos related to

Pageof 25
Sort By:
Nature Reviews. Clinical Oncology|December 21, 2018
Advances in prediction for ovarian cancer treatment stratificationAmit M Oza
Clinical Advances in Hematology & Oncology : H&O|June 20, 2020
The role of maintenance therapy in ovarian cancerAmit M Oza
Novartis Foundation Symposium|May 7, 2002
Clinical development of P glycoprotein modulators in oncologyAmit M Oza
Drugs|September 22, 2023
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future OptionsVikas Garg, Amit M Oza
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2023
Assessment of Homologous Recombination Deficiency in Ovarian CancerVikas Garg, Amit M Oza
Current Opinion in Oncology|June 16, 2011
Recent advances in systemic therapy for advanced endometrial cancerDaliah Tsoref, Amit M Oza
The Lancet. Oncology|June 30, 2022
Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations - Authors' replyRebecca Kristeleit, Amit M Oza
The Lancet. Oncology|April 18, 2015
Targeting the microenvironment in ovarian cancerStephanie Lheureux, Amit M Oza
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2021
Wee1 Inhibition in Recurrent Serous Uterine Cancer: Science Paving the Way in a Challenging DiseaseAinhoa Madariaga, Amit M Oza
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2020
Measurement Tool of Chemotherapy Sensitivity in Advanced Ovarian CancerTaymaa May, Amit M Oza
Pageof 25

Showing results (1-10 of 250) with videos related to

Sort By:
Pageof 25
Nature Reviews. Clinical Oncology|December 21, 2018
Advances in prediction for ovarian cancer treatment stratificationAmit M Oza
Clinical Advances in Hematology & Oncology : H&O|June 20, 2020
The role of maintenance therapy in ovarian cancerAmit M Oza
Novartis Foundation Symposium|May 7, 2002
Clinical development of P glycoprotein modulators in oncologyAmit M Oza
Drugs|September 22, 2023
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future OptionsVikas Garg, Amit M Oza
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2023
Assessment of Homologous Recombination Deficiency in Ovarian CancerVikas Garg, Amit M Oza
Current Opinion in Oncology|June 16, 2011
Recent advances in systemic therapy for advanced endometrial cancerDaliah Tsoref, Amit M Oza
The Lancet. Oncology|June 30, 2022
Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations - Authors' replyRebecca Kristeleit, Amit M Oza
The Lancet. Oncology|April 18, 2015
Targeting the microenvironment in ovarian cancerStephanie Lheureux, Amit M Oza
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2021
Wee1 Inhibition in Recurrent Serous Uterine Cancer: Science Paving the Way in a Challenging DiseaseAinhoa Madariaga, Amit M Oza
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2020
Measurement Tool of Chemotherapy Sensitivity in Advanced Ovarian CancerTaymaa May, Amit M Oza
Pageof 25